--- title: CDMO Daily News — October 1, 2026 slug: daily-news-2026-10-01-cdmo site: cdmo post_kind: news byline: BioBM description: October 1 CDMO daily: SK pharmteco Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing; Piramal Pharma Solutions Secures $1.75M Ontario… canonical_url: https://www.cdmo.directory/posts/daily-news-2026-10-01-cdmo published_at: 2026-10-01T00:00:19.827Z last_updated: 2026-10-01T00:02:26.268Z --- ### [SK pharmteco](/companies/skpharmteco) Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing - [SK pharmteco](/companies/skpharmteco) will invest over $200 million across five years to expand U.S. development labs, GMP manufacturing capacity for small molecules and APIs, and peptide purification with kilo-scale GMP capability operational by late 2026. - The investment includes new development laboratories, advanced liquid chromatography systems, modernized GMP suites, and green-technology infrastructure upgrades expected to create 100 long-term skilled jobs domestically. - Expansion complements SK pharmteco's recent opening of two advanced manufacturing facilities in Ireland for large-scale commercial small molecules and ultra-high-potency active pharmaceutical ingredients. **Operational Impact** [SK pharmteco](/companies/skpharmteco)'s new U.S. GMP peptide kilo-scale capacity (late 2026) and expanded small-molecule manufacturing suites reduce regional supply risk for CDMO customers seeking domestic, sustainable API and peptide sourcing through commercial scale. *Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/sk-pharmteco-to-invest-over-200m-in-u-s-over-next-5-years)* --- ### [Piramal Pharma Solutions](/companies/piramalpharmasolutions) Secures $1.75M Ontario Grant for Aurora API Site Expansion - [Piramal Pharma Solutions](/companies/piramalpharmasolutions) received $1.75M from Ontario's Life Sciences Scale-Up Fund to upgrade its Aurora, Canada drug substance manufacturing facility. - PPS is co-investing $5.31M total to enhance R&D, clinical API production, and commercial drug-substance capacity while creating 12 new jobs and protecting 183 existing roles. - Infrastructure upgrades will focus on sustainability, operational efficiency, and site modernization to strengthen domestic API production and manufacturing capabilities. **Operational Impact** Piramal's Aurora facility upgrade adds North American API manufacturing capacity for clinical and commercial supply, reinforcing domestic sourcing options for sponsors seeking Canadian-based drug-substance CDMO partners. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-receives-1-75m-ontario-investment-for-aurora-site)* --- ### [Axplora](/companies/axplora) Advances Exatecan GMP Supply Route for ADC Developers - [Axplora](/companies/axplora) completed first R&D batches of Exatecan and produced gram quantities as part of its Axotecan project to establish independent European supply. - Company targets validation batches by end of 2026 and initial GMP supply in late 2027, subject to technical, quality, and regulatory milestones. - Initiative addresses ADC developer demand for supply diversity, consistent quality, and shorter lead times for critical payload-linker materials. **Operational Impact** [Axplora](/companies/axplora)'s Exatecan GMP supply route entering validation phase by end of 2026 provides ADC developers with a European alternative to existing suppliers, reducing single-source risk for a critical payload material. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/axplora-completes-first-rd-batches-of-exatecan-for-adc-developers)* --- ### [Genezen](/companies/genezen) to Manufacture AAV9 Gene Therapy for N-of-1 ARCA2 Trial - [Genezen](/companies/genezen) will provide viral vector manufacturing and analytical capabilities for an AAV9 gene therapy targeting autosomal recessive spinocerebellar ataxia-2 (ARCA2), an ultra-rare disorder affecting ~25 patients worldwide. - The N-of-1 clinical trial, developed with University of Missouri's NextGen Precision Health initiative, leverages Genezen's accelerated manufacturing and release timeline expertise for small patient population programs. **Operational Impact** [Genezen](/companies/genezen)'s N-of-1 ARCA2 program showcases CDMO differentiation in ultra-rare gene therapy manufacturing where accelerated timelines and in-house analytical capabilities enable clinical trials for patient populations too small for traditional development pathways. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/genezen-partners-on-aav9-gene-therapy-for-ultra-rare-arca2-disorder)* ## References 1. [Contract Pharma Breaking News RSS — SK pharmteco Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing](https://www.contractpharma.com/breaking-news/sk-pharmteco-to-invest-over-200m-in-u-s-over-next-5-years) 2. [PharmaSource RSS — Piramal Pharma Solutions Secures $1.75M Ontario Grant for Aurora API Site Expansion](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-receives-1-75m-ontario-investment-for-aurora-site) 3. [PharmaSource RSS — Axplora Advances Exatecan GMP Supply Route for ADC Developers](https://pharmasource.global/content/news/cdmo-news/axplora-completes-first-rd-batches-of-exatecan-for-adc-developers) 4. [PharmaSource RSS — Genezen to Manufacture AAV9 Gene Therapy for N-of-1 ARCA2 Trial](https://pharmasource.global/content/news/cdmo-news/genezen-partners-on-aav9-gene-therapy-for-ultra-rare-arca2-disorder) Source: https://www.cdmo.directory/posts/daily-news-2026-10-01-cdmo